Funding for this research was provided by:
Received: 26 May 2020
Accepted: 17 June 2020
First Online: 15 July 2020
Ethics approval and consent to participate
: Not applicable.
: All authors have reviewed the manuscript and provided their consent to publish. All the patients mentioned in the manuscript gave their permissions to use full names.
: Dr. Canna received clinical trial support from AB2Bio. Dr. Schulert has received consulting fees from SOBI and Novartis (less than $10,000 each). Dr. Brunner has received consulting fees from Bristol-Myers Squibb, Pfizer, Janssen, Eli Lilly, Roche, and Novartis (less than $10,000 each). Dr. Grom has received consulting fees from SOBI and Novartis (less than $10,000 each) and research support from SOBI, Novartis, and AB2 Bio. Dr. Gadina has a Collaborative Research and Development Agreement related to JAK inhibitors with Pfizer. Dr. De Benedetti has received research grants from Abbvie, Pfizer, Eli-Lilly, Roche, Novartis, NovImmune, Sanofi, and SOBI. Dr. Rashmi Sinha serves as the president of <i>the SJIA Foundation</i>. No other disclosures relevant to this article were reported.